RA Capital Management is a venture capital and private equity firm investing in public and private healthcare and life science companies that is headquartered in Boston, Massachusetts and was founded in 2004 by Richard Aldrich.
According to Crunchbase (as of December 2019), RA Capital Management has made 114 investments, lead 28 investments, and made a total of 62 exits. Notable investments made by Ra Capital Management (as of December 2019) include: Audentes Therapeutics, 89bio, Bluebird Bio, Precision BioSciences, Moderna Therapeutics, Peloton Therapeutics, Orchard Therapeutics, Phathom Pharmaceuticals, Global Blood Therapeutics, and AveXis.
RA Capital Nexus Fund
On July 15, 2019 RA Capital Management announced raising $308 million for their RA Capital Nexus Fund. The fund increases the firms deal capiacity to $1 billion, and the total managed assets to about $2.5 billion. The firms plans on using the fund to invest in companies working on products and services realted to neurology, oncology, cardiovascular disease, and rare diseases.
A biopharmaceutical company that develops treatments for multi-drug resistant (MDR) bacterial infection
ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.
Nkarta Therapeutics is a biotechnology company using natural killer (NK) immune cells for cellular therapies.
Vor BioPharma is a biotechnology company developing hematopoietic stem cell therapy treatments for cancer.
Cancer screening company
Solid Biosciences is a Cambridge, Massachusetts-based biotechnology company.
Black Diamond Therapeutics is a Biotechnology company.
WhiteSwell is dedicated to advancing treatment of acute decompensated heart failure .
Braeburn Pharmaceuticals is a Plymouth, Pennsylvania-based company.
Prevail Therapeutics is a New York City-based company.
Stoke Therapeutics is a Bedford, Massachusetts-based company.
Imara is a Cambridge, Massachusetts-based company.
Akouos is a Brookline, Massachusetts-based company.
89Bio is a San Francisco-based company.
Andrew Levin, MD, PhD
Ben Dake, PhD
Chieze Ibeneche-Nnewihe, PhD
Derek DiRocco, PhD
Jake Simson, PhD
Jamie Kasuboski, PhD
Venture Senior Associate
Josh Resnick, MD
Mary Pat Connolly
Investment Research Coordinator
Matthew Hammond, PhD
Nathanial Brooks Horowitz
Corporate Development Manager
Peter Kolchinsky, PhD
Ryan Berry, PhD
Zach Scheiner, PhD
Documentaries, videos and podcasts